Drug Trial Radar · NCT07705737
Rademikibart IV for Acute Asthma and COPD Exacerbation
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 21, 2026
Primary completion
Dec 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Connect Biopharm LLCIndustry
- Sponsor type
- Industry
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
Conditions
- Asthma Acute
- COPD Exacerbation Acute
Interventions
RademikibartDrug
Single 300 mg dose as a 2-minute IV push
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in post-BD FEV1Time frame: 1 week
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Columbus Clinical Services, LLC
Miami, Florida · Active not recruiting
Pharmax Research of South Florida, Inc.
Miami, Florida · Recruiting
Washington University- Cardiovascular Imaging and Clinical Research Core Laboratory
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.